. Author manuscript; available in PMC: 2010 Jan 1.

Published in final edited form as: Osteoarthritis Cartilage. 2008 Jun 20;17(1):114–123. doi: 10.1016/j.joca.2008.05.006

Table 2.

Properties of constructs treated with IGF-I in phase I.

Group	WW (mg)	Thickness (mm)	Total Cells (×10⁶)	FI
Control	25.7±1.0	0.74±0.06	5.2±0.6	0.59±0.19
100 ng/ml Continuous	24.5±1.4	0.65±0.08	5.3±0.7	0.93±0.12^a
100 ng/ml Wk Rotat.	22.7±1.6^a	0.71±0.09	5.0±0.4	0.92±0.14^a
10 ng/ml Continuous	23.2±1.7^a	0.75±0.10	4.6±0.6	0.78±0.19^a
10 ng/ml Wk Rotat.	24.1±1.9	0.75±0.12	5.0±0.3	0.96±0.08^a

Significantly different from control

Wk Rotat., 2-wk rotation dosage; Col., total collagen